◇ Compound Reference
Base Form · 5mg
Body Protective Compound. Systemic angiogenesis activation and GI lining integrity support. Core to V-01 recovery protocol; available as physician-evaluated GI adjunct for V-03 and V-M2 metabolic protocols.
Base Form · 5mg per vial · dispensed after a physician review.
Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.
Body Protective Compound 157 is a 15-amino-acid synthetic peptide derived from human gastric juice protein BPGP. Originally identified for its cytoprotective action on the gastric mucosa, BPC-157 demonstrates broad regenerative activity across soft tissue, vasculature, and gastrointestinal lining.
Acts through nitric oxide pathway activation, growth hormone receptor sensitization, and VEGF (vascular endothelial growth factor) upregulation. The combined effect drives angiogenesis, fibroblast migration, and granulation tissue formation at injury sites.
Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05
These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.
Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
| Class | Synthetic pentadecapeptide (15 aa); BPC fragment |
| Studied mechanism | Associated with VEGFR2–Akt–eNOS signalling, ERK1/2 and FAK–paxillin pathways in preclinical models |
| Human pharmacokinetics | Not well-characterised - human half-life and bioavailability not robustly established in peer-reviewed literature |
| Evidence base | Predominantly preclinical (animal/in-vitro); limited controlled human data |
| Form | Lyophilized powder, reconstituted under clinical protocol |
| Regulatory status | Not an approved therapy; physician-supervised use only |
PRISMA-compliant systematic review (36 studies, 1993–2025) summarising the BPC-157 evidence base. The authors documented BPC-157's mechanistic profile (growth hormone receptor enhancement, angiogenesis modulation, anti-inflammatory pathways) across preclinical IBD, GI ulcer, NSAID-induced injury, fistula, and anastomotic models. Critically, the review states: "No clinical safety data is available to date" - i.e. despite extensive preclinical activity, controlled human safety and efficacy data remain absent in the modern peer-reviewed literature.
View on publisher ↗Early Croatian Phase I/II clinical trials (PL10, PL14736) explored BPC-157 in mild-to-moderate ulcerative colitis, reporting safety and tolerability signals in small cohorts. Important caveats: these trials were conducted primarily by BPC-157's discoverers and have not been independently replicated in Western peer-reviewed RCTs at scale; detailed trial reports have not appeared in major Western journals despite frequent reference in subsequent reviews. The 2024 Sikiric et al. review summarises three decades of work but is from the originating group. Independent confirmatory trials remain absent.
View on publisher ↗In-vitro study on isolated Achilles tendon fibroblasts. BPC-157 produced time- and dose-dependent upregulation of Growth Hormone Receptor expression at the mRNA and protein level, with increased fibroblast proliferation markers. Mechanistic and preclinical; does not constitute evidence of efficacy in human tissue repair.
View on publisher ↗Preclinical study mapping cellular pathways. Identified BPC-157 activity on the FAK–paxillin migration pathway, with enhanced cell outgrowth and survival in tendon-explant models. Cellular/animal level; human controlled trial evidence remains absent.
View on publisher ↗Comprehensive narrative review of BPC-157 wound-healing data across skin wounds, burns, diabetic ulcers, alkali burns, and a distinctive body of fistula-healing work (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, rectovaginal). Documents the angiogenic mechanism - BPC-157 upregulates VEGF-a and promotes endothelial proliferation and vascular tube formation, with an angiogenic effect exceeding standard agents in the sponge assay. Two important caveats: (1) the evidence is almost entirely animal (rat/mouse, some pig) - not human outcome data; (2) it is a review by the originating Zagreb group, and most primary citations are that group's own work, so it has not been independently replicated at scale. Note also that the same pro-angiogenic/VEGF action that drives healing is the basis for the theoretical oncologic caution discussed for any angiogenic compound.
View on publisher ↗Review proposing BPC-157 as a candidate for cancer cachexia (cancer-related muscle/fat wasting). In a C-26 colon-adenocarcinoma mouse model the peptide antagonised TNF-α and IL-6, cytokines central to cachexia. Preclinical and pre-clinical-trial - a proposal, not an outcome study - and from the originating (Sikiric) group.
View on publisher ↗In vitro: BPC-157 (2–10 ng) reduced human melanoma cell S-phase fraction by up to ~55% and decreased ERK phosphorylation - i.e. it acted as an antimitogenic agent INHIBITING the VEGF-MAPK proliferative signal in melanoma cells. A conference abstract (no full text), from the originating group; counterintuitive against the “BPC promotes angiogenesis” healing literature, which is why both directions matter.
View on publisher ↗A 2025 review in which the originating group directly addresses the tumour-risk speculation: it argues BPC-157 CONTROLS/MODULATES angiogenesis rather than driving tumorigenesis (e.g. it opposes corneal neovascularisation - “angiogenic privilege”), reports anti-tumour potential in vitro and in vivo per Folkman’s concept, and notes LD1 not achieved with no reported adverse effects. Important read: this is a defence authored by the compound’s originating group, so it answers but does not independently close the theoretical tumour-risk question.
View on publisher ↗BPC-157 is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.
Are you 18 years of age or older?